US Bancorp’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-830
| Closed | -$263K | – | 4143 |
|
|
2023
Q4 | $263K | Buy |
830
+169
| +26% | +$32.9K | ﹤0.01% | 1872 |
|
|
2023
Q3 | $112K | Sell |
661
-2,044
| -76% | -$384K | ﹤0.01% | 2095 |
|
|
2023
Q2 | $587K | Sell |
2,705
-194
| -7% | -$41.6K | ﹤0.01% | 1315 |
|
|
2023
Q1 | $527K | Sell |
2,899
-705
| -20% | -$135K | ﹤0.01% | 1378 |
|
|
2022
Q4 | $708K | Buy |
3,604
+19
| +0.5% | +$4.07K | ﹤0.01% | 1226 |
|
|
2022
Q3 | $807K | Sell |
3,585
-797
| -18% | -$161K | ﹤0.01% | 1153 |
|
|
2022
Q2 | $554K | Buy |
4,382
+3,762
| +607% | +$432K | ﹤0.01% | 1386 |
|
|
2022
Q1 | $79K | Buy |
620
+40
| +7% | +$4.5K | ﹤0.01% | 2392 |
|
|
2021
Q4 | $76K | Hold |
580
| – | – | ﹤0.01% | 2435 |
|
|
2021
Q3 | $71K | Sell |
580
-205
| -26% | -$23.7K | ﹤0.01% | 2472 |
|
|
2021
Q2 | $90K | Sell |
785
-1,580
| -67% | -$185K | ﹤0.01% | 2375 |
|
|
2021
Q1 | $284K | Sell |
2,365
-1,756
| -43% | -$199K | ﹤0.01% | 1772 |
|
|
2020
Q4 | $419K | Sell |
4,121
-1,375
| -25% | -$127K | ﹤0.01% | 1534 |
|
|
2020
Q3 | $425K | Buy |
5,496
+4,198
| +323% | +$358K | ﹤0.01% | 1413 |
|
|
2020
Q2 | $145K | Buy |
1,298
+249
| +24% | +$21.6K | ﹤0.01% | 1927 |
|
|
2020
Q1 | $76K | Buy |
1,049
+664
| +172% | +$56.8K | ﹤0.01% | 2162 |
|
|
2019
Q4 | $29K | Buy |
+385
| New | +$16.9K | ﹤0.01% | 2737 |
|
Other funds holding KRTX
US Bancorp's KRTX Position: Q1 2024 in Review
US Bancorp sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 830 shares — an estimated $263K sold.
US Bancorp first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $807K in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- US Bancorp reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- US Bancorp sold 830 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $263K.
- US Bancorp first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- US Bancorp's Karuna Therapeutics, Inc. Common Stock position peaked at $807K in Q3 2022.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.